Browse the evidence

A single-administration self-boosting microneedle patch delivering semaglutide sustains therapeutic plasma levels and induces weight loss in rats for one month, effectively simulating four separate weekly subcutaneous injections.

This research proposes a microneedle patch that delivers semaglutide (a weight-loss drug) through the skin. Instead of getting a shot every week, you apply a small patch once, and it releases the medication slowly over four weeks. In rats, this worked just as well as getting four separate shots. While promising for reducing pain and improving adherence, this is still experimental technology tested only on animals, not yet available for human use.

Precision nutrition strategies, including monitoring postprandial glycemic responses and gut microbiome composition, may attenuate unfavorable cardiovascular risk factors associated with menopause.

Consider how your body responds to specific foods after eating (postprandial response). While full precision nutrition testing may not be available, focusing on fiber, reducing sugar, and potentially incorporating isoflavone-rich foods (like soy) may support gut health and metabolic stability during menopause.

GLP-1 agonist administration in Type 1 Diabetes patients can precipitate Euglycemic Diabetic Ketoacidosis (EDKA) by suppressing gluconeogenesis and glycogenolysis, masking the hyperglycemia typically required for DKA diagnosis.

If you have Type 1 Diabetes and are taking a GLP-1 agonist (like Wegovy or Ozempic), be aware that you can develop Diabetic Ketoacidosis (DKA) even if your blood sugar looks normal. This is called Euglycemic DKA. If you experience nausea, vomiting, or abdominal pain, do not assume it is just a side effect or that your insulin is working. Check your blood ketones and seek medical attention if they are elevated, as standard DKA treatments (high insulin, no dextrose) may be dangerous without dextrose support.

Chronic stimulation of pancreatic beta-cells by incretin agonists may lead to beta-cell exhaustion, receptor downregulation, and potentially beta-cell failure over the long term.

While generally safe, long-term use of incretin medications may theoretically stress pancreatic beta-cells. Doctors monitor for this, but the long-term human data is still being gathered. It is important to discuss any concerns about long-term safety with your healthcare provider.

Chronic GIPR agonism may lead to desensitization that mimics functional antagonism, potentially explaining why both agonists and antagonists result in weight loss.

There is a theoretical possibility that long-term use of GIP-activating drugs could lead to receptor desensitization, acting like a blocker. However, current clinical evidence does not strongly support this in the brain, and these drugs remain effective for weight loss. Monitor your progress with your doctor.

Unimolecular tetra-receptor agonists (TC4) simultaneously activate GLP-1R, GIPR, GcgR, and Y2R, resulting in superior metabolic efficacy (weight loss and glycemic control) compared to mono- or dual-agonists by leveraging synergistic receptor engagement.

This research describes a new class of peptide drugs that target four metabolic receptors (GLP-1, GIP, Glucagon, and PYY) simultaneously. In preclinical studies, this approach showed strong potential for treating obesity and type 2 diabetes with fewer side effects like nausea than older drugs. It is not yet available for human use.

Tirzepatide administration is associated with novel postmarketing adverse events including palpitations, musculoskeletal pain, and headaches, which were not prominent in initial clinical trials.

If you experience palpitations, muscle pain, or headaches after starting Tirzepatide, report these to your doctor. These are not the typical stomach issues and may require dose adjustment or injection site changes.

Tirzepatide, a dual GLP-1/GIP receptor agonist, may modify the natural course of lipedema by targeting its underlying immunometabolic, inflammatory, and fibrotic pathophysiology, rather than solely reducing body weight.

If you have lipedema, especially with insulin resistance, talk to your doctor about tirzepatide. It’s not just for weight loss; it may help reduce the inflammation and fibrosis causing your pain and stiffness. Since it’s a newer treatment for lipedema, ask about clinical trials or off-label use if appropriate for your case.

Heterozygous variants in the POMC gene (specifically p.Arg90His, p.Ser94Gly, p.Ser94=, and p.Ala195=) are associated with an intermediate obesity phenotype in adults, likely due to haploinsufficiency affecting melanocortin peptide processing.

If you carry a heterozygous POMC variant, you may have an intermediate form of genetic obesity that responds differently to standard interventions. This information can help tailor your treatment plan, though functional validation of specific variants is still needed.

Tirzepatide as an adjunct to insulin in adults with Type 1 Diabetes and overweight/obesity produces significant body weight reduction and reduced insulin requirements, but current evidence is insufficient to establish durable glycaemic benefit or long-term safety.

For adults with Type 1 Diabetes and obesity, Tirzepatide is a promising tool for significant weight loss and reducing insulin needs. However, it is not yet proven to reliably improve long-term blood sugar control or safety. If used, it requires careful monitoring for side effects like nausea and potential risks like DKA, especially if insulin is reduced too aggressively. It is currently an investigational option, not a standard of care.

BPC-157 accelerates tissue repair (tendons, muscles, ligaments, GI mucosa) by stimulating angiogenesis and modulating inflammation, though it lacks FDA approval and robust human clinical trials.

BPC-157 is a peptide studied for its ability to speed up the healing of tendons, muscles, and gut lining. While animal studies show promising results for tissue repair, it is not yet approved by the FDA for human use. It is sometimes used off-label in sports medicine, but robust human clinical trials are still needed to confirm its safety and efficacy.

In specific preclinical models (OVX rats, T2D mice), high-dose GLP-1 agonists can improve bone mass and microarchitecture, but these effects require doses much higher than those approved for human obesity treatment.

Animal studies show GLP-1s *can* help bones, but only at doses far higher than what humans take. This suggests the drug itself isn't a 'bone builder' at standard doses, and the bone loss seen in humans is likely due to weight loss, not a direct toxic effect of the drug.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, can cause immediate, systemic IgE-mediated hypersensitivity reactions (including urticaria and pruritus) shortly after the initial dose.

If you are prescribed Tirzepatide, be aware that a small percentage of users (1-2%) may experience an allergic reaction, such as hives or itching, shortly after the injection. This can happen even if you tolerated other GLP-1 drugs like semaglutide. If you develop a rash, hives, or difficulty breathing within minutes to hours of your dose, seek medical attention immediately and discontinue the drug.

The optimal ratio of GLP-1 to glucagon/GIP agonism in combination therapies is unknown, and the balance between efficacy (liver fat reduction) and safety (hyperglycemia, side effects) remains a key challenge.

There is no single 'best' combination therapy yet. The field is still debating whether to maximize GLP-1, add glucagon, or add GIP. Current trials are testing different ratios (e.g., 1:1 vs 5:1 GLP-1:glucagon). Patients should expect that these therapies are evolving and that side effects (nausea, hyperglycemia) may limit the dose that can be tolerated.

GABA signaling can induce the transdifferentiation of alpha cells into beta-like cells, potentially reversing chemically induced diabetes in vivo.

There is experimental evidence that GABA, a neurotransmitter, might help convert alpha cells (which raise blood sugar) into beta-like cells (which lower blood sugar) in diabetic mice. However, the paper also notes that other studies found no such regeneration with long-term GABA or artesunate administration. This remains a research area, not a current treatment option for humans.

Liraglutide shows a statistically significant disproportionality signal for completed suicide, but this is likely due to statistical fragility, small case numbers, and notoriety bias rather than a true pharmacological effect.

While Liraglutide shows a statistical signal for completed suicide in reporting databases, this is based on a very small number of cases (14) and is likely influenced by reporting bias. It should not be interpreted as evidence of increased risk.

Tirzepatide mitigates ischemic stroke damage by restoring Blood-Brain Barrier (BBB) integrity via Claudin-1 expression and reducing neuroinflammation.

This finding is currently limited to animal studies. While promising for stroke recovery, it does not yet translate to a standard human treatment protocol for acute stroke.

Beta-amyrin acetate, a compound derived from the medicinal fungus Poria cocos, acts as a putative antagonist of the Neuropeptide Y1 receptor (Y1R) by binding to the orthosteric site with high affinity, potentially inhibiting feeding behavior associated with obesity.

Beta-amyrin acetate is a specific chemical compound found in the fungus Poria cocos. Current research is purely computational (computer simulations), predicting it might block a specific brain receptor (Y1R) involved in hunger. There is no human dosing protocol or clinical evidence yet; do not use this as a weight loss treatment based on this paper alone.

Non-peptide small molecule agonists targeting the GLP-1 receptor orthosteric site can achieve binding affinities and stability comparable to or exceeding existing peptide-based GLP-1RAs, suggesting a viable mechanism for oral administration.

This paper does not offer a current treatment but identifies potential oral drug candidates. It suggests that future oral GLP-1 medications may exist that are as effective as current injectables, addressing the common desire to avoid injections.

The LPAR1 antagonist EPGN2154, administered orally at 10 mg/kg, significantly reduces hepatic fibrosis and improves liver histology in preclinical NASH models, independent of body weight loss.

This research identifies a specific drug candidate (EPGN2154) that targets liver fibrosis directly through receptor antagonism, rather than just reducing body weight. While not yet available for humans, it highlights that treating NASH may require specific molecular interventions beyond just weight loss, particularly for fibrosis regression.

Combination therapy of the LPAR1 antagonist EPGN2154 and the GLP-1 agonist Semaglutide results in the maximum body weight loss and fat mass reduction in diet-induced obese mice, outperforming either drug alone.

Combining a GLP-1 agonist (like Semaglutide) with an LPAR1 antagonist (like EPGN2154) appears to maximize weight loss in preclinical models, potentially offering a synergistic effect for obesity management.

Self-administered overdose of Semaglutide (up to 8x the weekly dose) can cause multiorgan failure, including acute kidney injury, cholestatic liver dysfunction, and gastrointestinal bleeding, in patients with Type 2 Diabetes.

If you are using Semaglutide, never inject more than the prescribed weekly dose, even if you feel you need to 'catch up' or are experiencing side effects. The delivery pen allows you to inject multiple times, which can lead to life-threatening organ failure. If you feel dysphoric or suicidal, seek immediate help and do not attempt to self-medicate or overdose.

Once-weekly subcutaneous semaglutide 2.4 mg produces clinically significant, sustained weight loss (mean -10.2% at 208 weeks) in adults with preexisting cardiovascular disease and obesity/overweight without diabetes, compared to placebo.

If you have heart disease and are overweight or obese (even without diabetes), once-weekly semaglutide 2.4 mg can help you lose about 10% of your body weight over 4 years, which is significantly more than placebo. This benefit is seen across different sexes, races, and BMI categories, though those with lower starting BMI might stop the medication more often due to side effects or lack of motivation. The key is that it works sustainably for cardiovascular health.

Semaglutide (2.4 mg/week) induces significant weight loss (mean -10.09% body weight) and improves cardiometabolic markers (BMI, waist circumference, blood pressure, CRP, lipids) in obese or overweight non-diabetic adults, with efficacy increasing with dose.

For non-diabetic adults with obesity, once-weekly subcutaneous semaglutide (2.4 mg) is a highly effective treatment for weight loss, averaging a 10% reduction in body weight. It also improves blood pressure, inflammation (CRP), and lipid profiles. While gastrointestinal side effects like nausea are common, they are typically transient. The treatment is dose-dependent, with higher doses yielding greater weight loss.